Axena Health, a Newton, MA-based medical device company focused on female pelvic health, closed on an additional $9.4m in its Series A funding.
The round was led by Cross-Border Impact Ventures (CBIV) alongside existing investors AXA IM Alts through its Global Healthcare Private Equity Strategy, KOFA Healthcare and Avestria Ventures. Donna Parr, managing director and partner at CBIV, is joining Axena Health’s board of directors as part of its investment. Donna Parr, managing director and partner at CBIV, is joining Axena Health’s board of directors as part of its investment.
The company intends to use the funds to expand its offerings and development efforts.
Led by CEO Jim O’Connor, Axena Health is dedicated to improving the lives of women with pelvic floor disorders. Its flagship product, the Leva® Pelvic Health System, offers a first-line treatment for urinary incontinence (UI) and chronic fecal incontinence (FI), underreported conditions affecting over 78 million and 12 million women in the U.S. alone.
The technology enables non-invasive, drug-free treatment via precise visualization of movement in real time during pelvic floor muscle training, while monitoring usage and progress.
FinSMEs
04/06/2024